Newsroom

LATEST PUBLICATIONS

Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3 ITD mutated AML

2025-05-09T09:20:30-07:00May 8th, 2025|

Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina^® MiSeq^TM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay

2026-01-07T13:13:14-08:00November 8th, 2024|

Performance Comparison of Invivoscribe’s LymphoTrack^® Assays Between Complete Genomics DNBSEQ-G99 and Illumina^® MiSeq^TM NGS Platforms

2026-04-20T09:02:18-07:00November 8th, 2024|

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

2026-04-20T09:08:04-07:00June 21st, 2024|

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

2026-04-20T09:04:28-07:00May 2nd, 2024|

Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay

2026-03-09T18:44:44-07:00April 22nd, 2025|

Invivoscribe Announces Registration of the LeukoStrat^® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland

2026-03-09T18:48:48-07:00March 27th, 2025|

EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA

2024-10-08T03:14:44-07:00October 8th, 2024|

Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML

2026-03-09T18:43:04-07:00May 8th, 2024|

Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA

2025-08-26T07:35:25-07:00July 21st, 2023|

16th JSH International Symposium

May 15 – 16, 2026
Kamakura, Japan
Attending

ASCO

May 29-Jun 3, 2026
Chicago, IL
Exhibiting
Meet with our team at ASCO

Festival of Genomics, Biodata & AI

Jun 3-4, 2026
Boston, MA
Exhibiting
Meet our team

The 66th Annual Meeting of the Japanese Society of Lymphoma Research

Jun 4 – 6, 2026
Tokyo, Japan
Attending

EHA

Jun 11-14, 2026
Stockholm, Sweden
Exhibiting
Meet with our team at EHA

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Newsroom

Newsroom

LATEST PUBLICATIONS

LATEST PRESS

CONFERENCES

16th JSH International Symposium

ASCO

Festival of Genomics, Biodata & AI

The 66th Annual Meeting of the Japanese Society of Lymphoma Research

EHA

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.